Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Pharm Biol ; 49(4): 437-44, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21388234

RESUMEN

CONTEXT: Cynanchum taiwanianum T. Yamaza (Asclepiadaceae) is a medicinal herb used in folk medicine for the treatment of several inflammation-related diseases such as hepatitis and dermatitis in Taiwan. OBJECTIVE: In the present study, we investigated the anti-inflammatory effect of C. taiwanianum T. Yamaza rhizome aqueous extract (CTAE). MATERIALS AND METHODS: The present study investigated the anti-inflammatory effect of CTAE using IL-1ß-induced NRK-52E cells. Production of NO and PGE(2) by ELISA, the mRNA and protein expression of iNOS and COX-2, phosphorylation of IκBα, and activation of NF-κB by RT-PCR and western blotting were determined. RESULTS: The CTAE significantly (P < 0.05) inhibited NO and PGE(2) production (decreased by 46.1% and 51%, respectively), and also significantly (P < 0.05) attenuated protein and mRNA expression of iNOS and COX-2 (decreased by 90% and 55% for iNOS and by 72% and 74%% for COX-2, respectively) in IL-1ß-induced NRK-52E cells, in a dose-dependent manner, without obvious cytotoxic effects. Furthermore, the CTAE suppressed the NF-κB nuclear translocation, in terms of inhibition of IκBα phosphorylation. DISCUSSION AND CONCLUSION: Our results provided evidence for its folkloric uses and suggest that the anti-inflammatory activities of CTAE may result from the inhibition of inflammatory mediators, such as NO and PGE(2), and an upstream suppression of a NF-κB-dependent mechanism, might be involved.


Asunto(s)
Antiinflamatorios/farmacología , Cynanchum , Interleucina-1beta/metabolismo , FN-kappa B/antagonistas & inhibidores , Fitoterapia , Extractos Vegetales/farmacología , Animales , Antiinflamatorios/toxicidad , Supervivencia Celular/efectos de los fármacos , Dinoprostona/antagonistas & inhibidores , Riñón/efectos de los fármacos , Medicina Tradicional , Óxido Nitroso/antagonistas & inhibidores , Proteínas Nucleares/análisis , Fosforilación/efectos de los fármacos , Extractos Vegetales/toxicidad , Plantas Medicinales , Ratas , Rizoma
2.
Pharm Biol ; 48(2): 221-6, 2010 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-20645845

RESUMEN

This study evaluates the possible potency of the anti-hyperlipidemic effect of spider brake [(Pteris multifida Poiret (Pteridaceae)]. We investigated this by feeding the hyperlipidemic Sprague-Dawley rats, caused by a high cholesterol diet, with lyophilized powder of spider brake (LSB) and compared the result with the rats fed with beta-sitosterol. The results indicated that the administration of lyophilized powder of spider brake (LSB) lowered the hyperlipidemic level on rats. The relative weights of the liver, adipose tissue, and relative adipose tissue of 10% substitutions of LSB group (LSB-10) showed a significant decrease (P < 0.05) by 6%, 15.9%, and 14.3% in contrast to the untreated counterparts (control), respectively. A significantly lower (P < 0.05) plasma TG, low density lipoprotein cholesterol, low density lipoprotein cholesterol/high density lipoprotein cholesterol ratio, liver CH, and TG contents were also observed in LSB-10 compared to the untreated counterparts (by 36.8%, 21%, 18.7%, 10.2% and 14.3% reduction, respectively). Simultaneously, the wet fecal weight, dry fecal weight, nitrogen compounds, excretion of neutral steroids, and bile acids significantly (P < 0.05) increased by 9.6%, 10.6%, 23.7%, 9.7%, and 3.4% respectively. The results showed that LSB could cause not only a reduction in CH and TG, but also could increase the excretion of lipids and metabolic by-products via the intestinal tract.


Asunto(s)
Medicamentos Herbarios Chinos/uso terapéutico , Hiperlipidemias/prevención & control , Hipolipemiantes/uso terapéutico , Extractos Vegetales/uso terapéutico , Pteris/química , Tejido Adiposo/efectos de los fármacos , Tejido Adiposo/patología , Adiposidad/efectos de los fármacos , Animales , Ácidos y Sales Biliares/análisis , Relación Dosis-Respuesta a Droga , Medicamentos Herbarios Chinos/administración & dosificación , Medicamentos Herbarios Chinos/química , Heces/química , Hiperlipidemias/inducido químicamente , Hiperlipidemias/metabolismo , Hiperlipidemias/patología , Hipolipemiantes/administración & dosificación , Hipolipemiantes/química , Metabolismo de los Lípidos/efectos de los fármacos , Lípidos/sangre , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Masculino , Nitrógeno/análisis , Tamaño de los Órganos/efectos de los fármacos , Extractos Vegetales/administración & dosificación , Extractos Vegetales/química , Polvos , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Esteroles/análisis
3.
Int Immunopharmacol ; 15(1): 106-13, 2013 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-23142091

RESUMEN

The hepatoprotective effects of an aqueous extract formula (AEF) derived from Artemisia capillaris, Lonicera japonica and Silybum marianum (ratio 1:1:1) were evaluated by its antioxidant properties and its attenuation of carbon tetrachloride (CCl(4))-induced liver damage in rats. The antioxidant analyses revealed that the AEF showed higher 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical and superoxide anion radical scavenging activities as well as ferric reducing antioxidant potential (FRAP) and Trolox equivalent antioxidant capacity (TEAC) compared with the individual herbs, suggesting a synergism in antioxidation between the three herbs. The animal experiments showed that the CCl(4) treatment increased serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, but decreased triglyceride (TG) and glutathione (GSH) levels as well as glutathione peroxidase (GPx), superoxide dismutase (SOD) and catalase (CAT) activities. However, AEF administration can successfully lower serum ALT and AST activities, restore the GSH level, ameliorate or restore GPx and CAT activities as well as improve SOD action depending on AEF dosage. Histological examination of liver showed that CCl(4) increased the extent of bile duct proliferation, necrosis, fibrosis and fatty vacuolation throughout the liver, but AEF can improve bile duct proliferation, vacuolation and fibrosis, and restore necrosis. The present study demonstrated the hepatoprotective potential of AEF as an alternative to the traditional silymarin.


Asunto(s)
Antioxidantes/uso terapéutico , Artemisia , Enfermedad Hepática Inducida por Sustancias y Drogas/tratamiento farmacológico , Medicamentos Herbarios Chinos/uso terapéutico , Lonicera , Silybum marianum , Alanina Transaminasa/sangre , Animales , Aspartato Aminotransferasas/sangre , Tetracloruro de Carbono , Catalasa/metabolismo , Enfermedad Hepática Inducida por Sustancias y Drogas/metabolismo , Enfermedad Hepática Inducida por Sustancias y Drogas/patología , Quimioterapia Combinada , Glutatión/metabolismo , Glutatión Peroxidasa/metabolismo , Masculino , Fitoterapia , Ratas , Ratas Sprague-Dawley , Superóxido Dismutasa/metabolismo , Triglicéridos/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA